Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC53H67N11O7S |
InChIKeyMWVNDEBEHBRZEC-WWTLGBROSA-N |
CAS Registry2229974-73-4 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | US | 30 Nov 2022 |